KR20140116665A - A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening - Google Patents

A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening Download PDF

Info

Publication number
KR20140116665A
KR20140116665A KR1020130031527A KR20130031527A KR20140116665A KR 20140116665 A KR20140116665 A KR 20140116665A KR 1020130031527 A KR1020130031527 A KR 1020130031527A KR 20130031527 A KR20130031527 A KR 20130031527A KR 20140116665 A KR20140116665 A KR 20140116665A
Authority
KR
South Korea
Prior art keywords
skin
acid
extract
lotion
composition
Prior art date
Application number
KR1020130031527A
Other languages
Korean (ko)
Other versions
KR101510092B1 (en
Inventor
손준호
박태순
김동희
황주영
이윤호
Original Assignee
재단법인 한국한방산업진흥원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 한국한방산업진흥원 filed Critical 재단법인 한국한방산업진흥원
Priority to KR20130031527A priority Critical patent/KR101510092B1/en
Publication of KR20140116665A publication Critical patent/KR20140116665A/en
Application granted granted Critical
Publication of KR101510092B1 publication Critical patent/KR101510092B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a composition comprising a seed extract of Rubus coreanus as an active ingredient and, more specifically, to a pharmaceutical composition for external skin application or a cosmetic composition for skin whitening and preventing and treating skin aging by confirming that the Rubus coreanus seed extract has tyrosinase inhibitory activity, elastase inhibitory activity, cellular tyrosinase inhibitory activity, and pro-collagen biosynthesis inhibitory activity.

Description

복분자 씨 추출물을 유효성분으로 함유하는 미백 및 피부노화의 예방 및 치료용 조성물 {A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening}FIELD OF THE INVENTION The present invention relates to a composition for preventing and treating skin whitening and skin aging comprising an extract of Rubus coreanus as an active ingredient,

본 발명은 복분자 씨 추출물을 유효성분으로 함유하는 미백 및 피부노화의 예방 및 치료용 조성물을 제공한다.The present invention provides a composition for preventing and treating whitening and skin aging comprising an extract of bokbunja as an active ingredient.

[문헌 1] Kligman LH. (1996) The hairless mouse model for photoaging. Clinics in dermatology. 14(2), 183-195[Document 1] Kligman LH. (1996) The hairless mouse model for photoaging. Clinics in dermatology . 14 (2), 183-195

[문헌 2] Smith, LT, Holbrook, KA, Madri, JA. (1986) Collagen types Ⅰ,Ⅲ, and Ⅴ in human embryonic and fetal skin. Am J Anat. 175(4), 507-521.[Literature 2] Smith, LT, Holbrook, KA, Madri, JA. (1986) Collagen types I, III, and V in human embryonic and fetal skin. Am J Anat . 175 (4), 507-521.

[문헌 3]Chung JH. (2001) Modulation of collagen metabolism in aged and photoaged human skin in vivo. J Invest Dermatol. 117, 1218-1224.]. [Literature 3] Chung JH. (2001) Modulation of collagen metabolism in aged and photoaged human skin in vivo. J Invest Dermatol . 117, 1218-1224.].

[문헌 4]Colin R, (2000) Goding Mitf from neural crest to melanoma : signal transduction and transcription in the melanocyte lineage. Genes & Dev . 14, 1712-1728.[4] Colin R, (2000) Goding Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes & Dev . 14, 1712-1728.

[문헌 5] Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. (1995) Expression of tyrosinase, tyrosinase related protein 1 and 2 (TRP1 and TRP2), silver protein and a melanogenic inhibitor regulates melanogenesis in human melanoma cells. Pigment . Cell . Res. 8, 97-104.[Literature 5] Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. (1995) Expression of tyrosinase, tyrosinase related protein 1 and 2 (TRP1 and TRP2), silver protein and a melanogenic inhibitor regulates melanogenesis in human melanoma cells. Pigment . Cell . Res . 8, 97-104.

[문헌 6] Roesler WJ, Park EA, McFie PJ. (1998) Characterixation of CCAAT enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator. J. Biol . Chem. 273, 14950-14957.[Literature 6] Roesler WJ, Park EA, McFie PJ. (1998) Characterixation of CCAAT enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator. J. Biol . Chem . 273, 14950-14957.

[문헌 7] Rose Busca, Robert Ballotti. (2000) Cyclic AMP a key messenger in the regylation of skin pigmentation. Pigment Cell Res. 13, 60-69.[Literature 7] Rose Busca, Robert Ballotti. (2000) Cyclic AMP a key messenger in the regylation of skin pigmentation. Pigment Cell Res . 13, 60-69.

[문헌 8] Hunt G, Todd C, Gresswell JE, Thidy AJ. (1994) α-MSH and its analog Nle4DPhe7 α-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J. Cell . Sci. 107, 205-211.[Document 8] Hunt G, Todd C, Gresswell JE, Thidy AJ. (1994) α-MSH and its analog Nle 4 DPhe 7 α-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J. Cell . Sci . 107, 205-211.

[문헌 9] Lee NH, Yang HC, Bu HJ, Jung DS, Lee SJ, Riu KZ. (2001) Screening of the tyrosinase inhibition and hyaluronidase inhibition activities and radical scavenging effects using plants in Cheju. Kor . J. Pharmacogn . 32(3), 175-180.[9] Lee NH, Yang HC, Bu HJ, Jung DS, Lee SJ, Riu KZ. (2001) Screening of the tyrosinase inhibitory and hyaluronidase inhibitory activities and radical scavenging effects using plants in Cheju. Kor . J. Pharmacogn . 32 (3), 175-180.

[문헌 10]An BJ, Lee CE, Son JH, Lee JY, Choi GH and Park TS. (2005) Antioxidant, anticancer and tyrosinase inhibition activities of extracts from Rhododendron mucronulatum T. J. Korean Soc . Appl . Biol. Chem . 48(3), 280-284. [Literature 10] An BJ, Lee CE, Son JH, Lee JY, Choi GH and Park TS. (2005) Antioxidant, anticancer and tyrosinase inhibition activities of extracts from Rhododendron mucronulatum T. J. Korean Soc . Appl . Biol. Chem . 48 (3), 280-284.

[문헌 11]Tsuji N, Moriwaki S, Suzuki Y, Takema Y and Imokawa G. (2001) The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity. Photochem . Photobiol . 74(2), 283-290.[11] Tsuji N, Moriwaki S, Suzuki Y, Takema Y and Imokawa G. (2001) The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity. Photochem . Photobiol . 74 (2), 283-290.

[문헌 12] Kwak YJ, Lee DH, Kim NM and Lee JS. (2005) Screening and extraction condition of anti-skin aging elastase inhibitor from medicinal plants. Korean J. Medicinal Crop Sci . 13(6), 213-216[Document 12] Kwak YJ, Lee DH, Kim NM and Lee JS. (2005) Screening and extraction condition of anti-skin aging elastase inhibitor from medicinal plants. Korean J. Medicinal Crop Sci . 13 (6), 213-216

[문헌 13] Kim MJ, Kim JY, Choi SW, Hong JT and Yoon KS. (2004) Anti-wrinkle effect of safflower (Cathamus tinctorius) seed extract. J. Soc . Cosmet . Scientisis Korea . 30(1), 15-22.[Literature 13] Kim MJ, Kim JY, Choi SW, Hong JT and Yoon KS. (2004) Anti-wrinkle effect of safflower ( Cathamus tinctorius ) seed extract. J. Soc . Cosmet . Scientisis Korea . 30 (1), 15-22.

[문헌 14] K. C. Sung, (2011) A Study on the Pharmaceutical & Chemical Characteristics and Analysis of Natural Omija Extract, J . of the Korean Oil Chemists’ Soc., 28(3), 290]. [14] K. C. Sung, (2011) A Study on the Pharmaceutical & Chemical Characteristics and Analysis of Natural Omija Extract, J. of the Korean Oil Chemists' Soc., 28 (3), 290].

[문헌 15] H. M. Yang etc, (2007) A Comparison on the Inflammation Control Efficacy of native Bokbunja and foreign Bokbunja, Kor. j. Food Sci. Technol. Soc., 3, 342. [Literature 15] H. M. Yang et al., (2007) A Comparison on the Inflammation Control Efficacy of native Bokbunja and foreign Bokbunja, Kor. j. Food Sci. Technol. Soc., 3, 342.

[문헌 16] Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB. (1987) Evaluation of a tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47(4), 936-942.[16] Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB. (1987) Evaluation of a tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res . 47 (4), 936-942.

[문헌 17] Yagi A, Kanbara T and Morinobu N. (1986) The effect of tyrosinase inhibition for aloe. Planta Media. 3981, 517-519.[17] Yagi A, Kanbara T and Morinobu N. (1986) The effect of tyrosinase inhibition for aloe. Planta Media . 3981, 517-519.

[문헌 18] Akiu S, Suzuki Y, Asahara T, Fujinuma Y and Fukuda M. (1991) Inhibitory effect of arbutin on melanogenesis-biochemical study using cultured B16 melanoma cells. Nippon Hifuka Gakkai Zasshi . 101(6), 609-613[Literature 18] Akiu S, Suzuki Y, Asahara T, Fujinuma Y and Fukuda M. (1991) Inhibitory effect of arbutin on melanogenesis-biochemical study using cultured B16 melanoma cells. Nippon Hifuka Gakkai Zasshi . 101 (6), 609-613

[문헌 19] Hosoi J. Abe E, Suda T and Kuroki T. (1985) Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res. 45(4), 1474-1478[19] Hosoi J. Abe E, Suda T and Kuroki T. (1985) Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res . 45 (4), 1474-1478

[문헌 20] Cannell RJP, Kellan SJ, Owsianks AM and Walker JM. (1988) Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Media. 54(1), 10-14[Document 20] Cannell RJP, Kellan SJ, Owsians AM and Walker JM. (1988) Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Media . 54 (1), 10-14

[문헌 21] Kim JE. (2003) Effect of epigallocagechin-3-gallate on heat-modulated type Ⅰprocollagen, MMP-1, and TIMP-1 expression in cultured human dermal fibroblasts. Korea University. Seoul, Korea.
[Literature 21] Kim JE. (2003) Effect of epigallocatechin-3-gallate on heat-modulated type Ⅰprocollagen, MMP-1, and TIMP-1 expression in cultured human dermal fibroblasts. Korea University. Seoul, Korea.

피부 노화(skin aging)는 피부 진피층에 존재하는 세포외기질(extracellular matrix)의 구조적인 변화로 발생되는데 [Kligman LH. (1996) The hairless mouse model for photoaging. Clinics in dermatology. 14(2), 183-195.] 구성요소 중 탄력섬유(elastic fiber)의 변성과 교원질(collagen) 양의 감소가 피부의 주름을 야기한다[Smith, LT, Holbrook, KA, Madri, JA. (1986) Collagen types Ⅰ,Ⅲ, and Ⅴ in human embryonic and fetal skin. Am J Anat. 175(4), 507-521.]. 또한, 피부의 노화를 이끄는 주요 요인 중에는 콜라겐 (collagen)의 감소와 관련하여 자외선이나 스트레스에 의한 활성산소의 생성을 들 수 있다. 또한 UV (Ultraviolet; 자외선)에 의한 피부 손상이나 노화 또는 발암으로부터 신체를 보호하기 위한 멜라닌의 생성은 색소의 합성이나 분포의 기능에 장애가 있을 경우 다양한 피부 질환을 유발하게 되며, 과도한 색소의 침착은 흑색종, 주근깨, 노인성 검버섯 등을 생성시킨다. 최근에 사람들의 미적 욕구와 건강에 대한 관심이 증가하면서 향장업계에서는 멜라닌의 생성을 억제하는 기능성화장품의 개발에 대한관심이 점점 높아지고 있다[Chung JH. (2001) Modulation of collagen metabolism in aged and photoaged human skin in vivo. J Invest Dermatol. 117, 1218-1224.]. Skin aging is caused by a structural change in the extracellular matrix present in the dermal layer of the skin [Kligman LH. (1996) The hairless mouse model for photoaging. Clinics in dermatology . 14 (2), 183-195.) The denaturation of elastic fibers and the reduction of the amount of collagen in the components cause wrinkles of the skin [Smith, LT, Holbrook, KA, Madri, JA. (1986) Collagen types I, III, and V in human embryonic and fetal skin. Am J Anat . 175 (4), 507-521. Among the major factors leading to skin aging is the generation of active oxygen by ultraviolet rays or stress related to reduction of collagen. In addition, the production of melanin to protect the body from skin damage, aging or cancer caused by UV (ultraviolet) causes various skin diseases when the function of pigment synthesis or distribution is obstructed, Sponges, freckles, and senile spots. In recent years, interest in the aesthetic desires and health of people has been increasing, and there has been a growing interest in the development of functional cosmetics that inhibit the production of melanin [Chung JH. (2001) Modulation of collagen metabolism in aged and photoaged human skin in vivo. J Invest Dermatol . 117, 1218-1224.].

피부의 색조를 결정하는 주요한 인자인 멜라닌(melanin)은 표피 기저층의 melanocyte라고 불리는 색소세포내의 melanosome에서 생합성 된다. 멜라닌을 합성하는데 있어서의 출발물질은 아미노산의 일종인 tyrosine이다. Tyrosine은 멜라닌 세포내에서의 tyrosinase에 의해 L-3,4-dihydroxyl phenylalanine(DOPA), DOPA quinone으로 산화된다. 그 후 DOPA quinone이 DOPA chrome, 5,6-dihydroxyindole, indole-5,6-quinone이 되고, 이어서 indole-5,6-quinone으로의 중합에 의해 melanin을 생성하는 것으로 알려져 있다[Colin R, (2000) Goding Mitf from neural crest to melanoma : signal transduction and transcription in the melanocyte lineage. Genes & Dev . 14, 1712-1728.].Melanin, a key determinant of skin tone, is biosynthesized in melanosomes in pigmented cells called melanocytes of the epidermal basal layer. The starting material for the synthesis of melanin is tyrosine, an amino acid. Tyrosine is oxidized by tyrosinase in melanocytes to L-3,4-dihydroxyl phenylalanine (DOPA) and DOPA quinone. It is known that DOPA quinone is then converted to DOPA chrome, 5,6-dihydroxyindole, indole-5,6-quinone and then melanin by polymerization with indole-5,6-quinone [Colin R, ) Goding Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes & Dev . 14, 1712-1728.].

또한 tyrosinase는 피부 멜라닌 생성에 있어서 매우 중요한 역할을 하고 있으며, melanosome 내에서 tyrosine을 산화시켜 DOPA를 만드는 tyrosine hydoxylase로, DOPA를 산화시켜 DOPA quinone을 만드는 DOPA oxidase로서 작용하여 멜라닌 중합체를 합성하는데 중요한 효소로 작용한다[Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. (1995) Expression of tyrosinase, tyrosinase related protein 1 and 2 (TRP1 and TRP2), silver protein and a melanogenic inhibitor regulates melanogenesis in human melanoma cells. Pigment . Cell . Res. 8, 97-104.] In addition, tyrosinase plays an important role in the formation of melanin in the skin. Tyrosine hydoxylase, which oxidizes tyrosine in melanosome to form DOPA, acts as a DOPA oxidase that oxidizes DOPA to form DOPA quinone. [Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. (1995) Expression of tyrosinase, tyrosinase related protein 1 and 2 (TRP1 and TRP2), silver protein and a melanogenic inhibitor regulates melanogenesis in human melanoma cells. Pigment . Cell . Res . 8, 97-104.]

현재 의학계나 화장품업계에서는 멜라닌(melanin) 과잉 생성을 억제하기 위해 많은 연구가 이루어지고 있으며, 지금까지 알려진 티로시나제 (tyrosinase)의 저해제로 히드로퀴논(hydroquinone), 4-히드록시아니솔(hydroxyanisole), 아스코르빈산 (ascorbic acid), 코지산(kojic acid), 아젤산 (azelaic acid) 등이 있으나, 피부 안전성, 제형 안정성 등의 문제로 제한된 양만 사용되고 있다[Roesler WJ, Park EA, McFie PJ. (1998) Characterixation of CCAAT enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator. J. Biol . Chem. 273, 14950-14957.]. 이에 따라 세포독성이 적으면서 멜라닌 합성을 감소시키고 동시에 비-돌연변이성(non-mutagenic) 미백제를 찾기 위한 연구가 진행되고 있으며, 특히 천연물질이 날로 각광받고 있다.Currently, many studies have been conducted in the medical and cosmetic industries to inhibit the production of melanin excess, and there have been known inhibitors of tyrosinase, such as hydroquinone, hydroxyanisole, Ascorbic acid, kojic acid, and azelaic acid. However, only limited amounts are used for problems such as skin safety and formulation stability [Roesler WJ, Park EA, McFie PJ. (1998) Characterixation of CCAAT enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator. J. Biol . Chem . 273, 14950-14957.]. Accordingly, studies have been made to find non-mutagenic whitening agents while reducing cytotoxicity and reducing melanin synthesis, and in particular, natural materials are attracting attention.

사람의 피부색을 결정하는 가장 중요한 요인인 멜라닌(melanin)은 피부의 광노화나 일광각화증을 억제할 뿐만 아니라,[Rose Busca, Robert Ballotti. (2000) Cyclic AMP a key messenger in the regylation of skin pigmentation. Pigment Cell Res. 13, 60-69.] 기미, 주근깨, 검버섯 등의 부분적인 hyperpigmentation을 일으키는 역할을 하고 있다.[Hunt G, Todd C, Gresswell JE, Thidy AJ. (1994) α-MSH and its analog Nle4DPhe7 α-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J. Cell . Sci. 107, 205-211.) 멜라닌은 표피 기저층에 존재하는 melanocyte 내의 소기관인 melanosome에서 생합성되며, melanocyte의 수지상 돌기를 통하여 주위의 keratinocyte로 전달되고, 피부의 각질층으로 이행한다[Lee NH, Yang HC, Bu HJ, Jung DS, Lee SJ, Riu KZ. (2001) Screening of the tyrosinase inhibition and hyaluronidase inhibition activities and radical scavenging effects using plants in Cheju. Kor . J. Pharmacogn . 32(3), 175-180.]. 상기의 색소 침착을 치유하기 위해 멜라닌 생성을 억제하는 hydroquinone, resorcinol 등의 페놀 유도체나, L-ascorbic acid와 그 유도체 및 kojic acid, arbutin, lactic acid, glucosamine, tunicamycin 등이 개발되었으나, 피부 저자극성이나 안정성에 문제가 있어 극히 제한된 양만 사용되고 있다[An BJ, Lee CE, Son JH, Lee JY, Choi GH and Park TS. (2005) Antioxidant, anticancer and tyrosinase inhibition activities of extracts from Rhododendron mucronulatum T. J. Korean Soc . Appl . Biol . Chem . 48(3), 280-284].Melanin, the most important factor in determining human skin color, not only inhibits skin photoaging and sunsclerosis [Rose Busca, Robert Ballotti. (2000) Cyclic AMP a key messenger in the regylation of skin pigmentation. Pigment Cell Res . 13, 60-69.] It is responsible for the partial hyperpigmentation of spots, freckles, black spots, etc. [Hunt G, Todd C, Gresswell JE, Thidy AJ. (1994) α-MSH and its analog Nle 4 DPhe 7 α-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J. Cell . Sci . 107, 205-211.) Melanin is biosynthesized in the melanocytes of the melanocytes in the basal layer of the epidermis, and is transferred to peripheral keratinocytes through the dendrites of melanocytes and migrates into the stratum corneum of the skin [Lee, NH, Yang, HC HJ, Jung DS, Lee SJ, Riu KZ. (2001) Screening of the tyrosinase inhibitory and hyaluronidase inhibitory activities and radical scavenging effects using plants in Cheju. Kor . J. Pharmacogn . 32 (3), 175-180.). L-ascorbic acid and its derivatives and kojic acid, arbutin, lactic acid, glucosamine, and tunicamycin have been developed to inhibit melanogenesis. There is a problem in stability and only a very limited amount is used [An BJ, Lee, JH, Lee JY, Choi GH and Park TS. (2005) Antioxidant, anticancer and tyrosinase inhibitory activities of extracts from Rhododendron mucronulatum T. J. Korean Soc . Appl . Biol . Chem . 48 (3), 280-284).

신체의 노화 중에서 피부 노화는 크게 2종류로 나눌 수 있다. 첫째는 내인성 피부 노화로서 세월이 흘러감에 따라 피할 수 없는 노화현상을 말하며, 두 번째는 광노화 및 외인성 피부 노화로서 햇빛에 지속적으로 노출되어 생기는 피부 손상을 말한다[Tsuji N, Moriwaki S, Suzuki Y, Takema Y and Imokawa G. (2001) The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity. Photochem . Photobiol . 74(2), 283-290.]. 피부의 진피조직 속에는 콜라겐과 엘라스틴이 그물망 구조를 형성하면서 피부의 탄력성을 유지시켜 주는데 나이, 자외선과 같은 내외적 스트레스로 인하여 탄력성, 윤택성이 감소하고 과다 발현된 엘라스타제(elastase)에 의하여 엘라스틴의 그물망 구조가 깨지게 되면 피부가 처지고 주름이 생기므로 피부 노화가 발생하게 된다[Kwak YJ, Lee DH, Kim NM and Lee JS. (2005) Screening and extraction condition of anti-skin aging elastase inhibitor from medicinal plants. Korean J. Medicinal Crop Sci . 13(6), 213-216.]. 그러므로 피부 노화의 주 원인중의 하나인 엘라스틴 분해효소인 엘라스타제의 활성을 저해시킴으로써 피부 노화를 억제할 수 있다. 그러므로 피부 노화의 주원인 중의 하나인 엘라스틴 분해효소인 엘라스타제의 활성을 저해시킴으로써 피부 노화를 억제할 수 있다[Kim MJ, Kim JY, Choi SW, Hong JT and Yoon KS. (2004) Anti-wrinkle effect of safflower (Cathamus tinctorius) seed extract. J. Soc . Cosmet . Scientisis Korea . 30(1), 15-22.].Skin aging can be roughly classified into two types among the aging of the body. The first is the aging phenomenon that can not be avoided due to the aging of the skin, and the second is skin aging caused by the exposure to sunlight as a photoaging and exogenous skin aging [Tsuji N, Moriwaki S, Suzuki Y, Takema Y and Imokawa G. (2001) The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity. Photochem . Photobiol . 74 (2), 283-290.]. In the dermis of the skin, collagen and elastin form a network structure to maintain the elasticity of the skin. The elasticity and the wettability are reduced due to the internal and external stresses such as age and ultraviolet rays, and the elasticity of elastin When the mesh structure breaks, the skin becomes sagged and wrinkles occur, resulting in skin aging [Kwak YJ, Lee DH, Kim NM and Lee JS. (2005) Screening and extraction condition of anti-skin aging elastase inhibitor from medicinal plants. Korean J. Medicinal Crop Sci . 13 (6), 213-216.). Therefore, skin aging can be inhibited by inhibiting the activity of elastase, elastase, which is one of the main causes of skin aging. Therefore, it is possible to inhibit skin aging by inhibiting the activity of elastase, an elastin degrading enzyme, which is one of the main causes of skin aging [Kim MJ, Kim JY, Choi SW, Hong JT and Yoon KS. (2004) Anti-wrinkle effect of safflower ( Cathamus tinctorius ) seed extract. J. Soc . Cosmet . Scientisis Korea . 30 (1), 15-22.).

한편, 복분자(Rubus coreanus M)는 한방에서 보간신, 명목, 이뇨제의 효능이 있고, 정력 감퇴, 유정, 빈뇨를 치료한다고 알려져 있으며, 성분으로는 카르본 산(carvone acid), 비타민 C 및 다당 등의 성분이 알려져 있다. (정보섭외 도해향약대사전, p652-654, 영림사, 1998)Rubus coreanus M is known to be effective in the treatment of interpoly, renal, and diuretic effects in a single room. It is known to treat depression, vomiting, and urinary frequency. Carvone acid, vitamin C and polysaccharides Are known. (Information and Communication, pp. 652-654, Young Lim, 1998)

복분자 딸기의 생리활성과 관련한 연구로는 줄기로부터 2종의 플라반(flavan)-3-올(ol)과 1종의 프로안토시아니딘 (proanthocyanidin) 및 1종의 엘라지탄닌 (ellagitanin)의 분리와 잎으로부터 4종의 플라보노이드(flavonoid) 등의 페놀(phenol)성 화합물의 분리가 있었으며, 열매의 생리활성 등에 대하여 보고되었다[K. C. Sung, (2011) A Study on the Pharmaceutical & Chemical Characteristics and Analysis of Natural Omija Extract, J . of the Korean Oil Chemists’ Soc., 28(3), 290]. Studies on the physiological activity of bokbunja strawberry have shown that two kinds of flavan-3-ol (ol), one proanthocyanidin and one ellagitanin Separation and separation of phenol compounds such as flavonoids from the leaves were reported, and the physiological activity of the fruits was reported [K. C. Sung, (2011) A Study on the Pharmaceutical & Chemical Characteristics and Analysis of Natural Omija Extract, J. of the Korean Oil Chemists' Soc., 28 (3), 290].

한편, 가공 식품으로의 개발에 관한 연구로는 복분자를 이용한 주류의 개발, 미숙 복분자 분말을 이용한 건면 제조 등의 연구가 수행되었다[H. M. Yang etc, (2007) A Comparison on the Inflammation Control Efficacy of native Bokbunja and foreign Bokbunja, Kor. j. Food Sci. Technol. Soc., 3, 342].
In the meantime, research on the development of processed foods has been carried out, such as the development of liquor using bokbunja, and the preparation of dry noodles using immature bokbunja powder [HM Yang et al., (2007) A Comparison on the Inflammation Control Efficacy of native Bokbunja and foreign Bokbunja, Kor. j. Food Sci. Technol. Soc., 3, 342].

본 연구에서는 복분자 씨에 대한 미백, 주름관련 활성 실험을 통해 화장품 소재로서의 활용성을 검증하였다.In this study, the whitening and wrinkle - related activities of the brambled seeds were verified as a cosmetic material.

그러나, 지금까지 상기 문헌 어디에서도 복분자 씨 추출물 추출물이 미백 및 피부노화 예방 및 치료 효과를 위한 조성물로서 사용가능하다고 교시되거나 기재된 바 없다.However, it has not been taught or described in the above-mentioned literatures that the bokbunja extract can be used as a composition for whitening and prevention of skin aging and therapeutic effect.

이에 본 발명자는 복분자 씨 추출물은 티로시나제 (Tyrosinase) 효소 저해 활성, 엘라스타제 (Elastase) 효소 저해활성, 세포 티로시나제 (celluar tyrosinase) 효소 저해활성, 멜라닌(melanin) 생합성 저해활성, 프로-콜라겐 (Pro-collagen) 생합성 저해 활성 등이 탁월함을 확인함으로써, 상기 조성물을 미백 및 피부노화의 예방 및 치료용 피부외용 약학조성물 또는 화장료 조성물로 유용하게 이용 가능함을 확인함으로써 본 발명을 완성하였다.
Thus, the present inventors have found that the bramblymus seed extract can be used as a medicament for inhibiting tyrosinase enzyme activity, elastase enzyme inhibition activity, celluli tyrosinase enzyme inhibition activity, melanin biosynthesis inhibiting activity, pro- collagen, and biosynthesis inhibitory activity, the present inventors have completed the present invention by confirming that the composition can be effectively used as an external dermatological pharmaceutical composition or cosmetic composition for prevention and treatment of whitening and skin aging.

상기 목적을 달성하기 위하여, 본 발명은 복분자 씨 추출물을 유효성분으로 함유하는 미백 및 피부노화 치료 및 예방용 피부 외용 약학조성물을 제공한다.In order to achieve the above object, the present invention provides a dermatological pharmaceutical composition for treatment and prevention of whitening and skin aging, which comprises an extract of bokbunja as an active ingredient.

본원에서 정의되는 "피부노화"는 주름살, 기미, 주근께, 자외선에 의한 피부 손상, 피부암, 바람직하게는, 주름살을 포함한다.As used herein, "skin aging" includes wrinkles, stains, muscle wounds, skin damage due to ultraviolet rays, skin cancer, and preferably wrinkles.

상기 추출물은 피부외용 약학조성물은 총 중량에 대하여 0.1 내지 50 중량%으로 포함함을 특징으로 한다.The extract of the present invention is characterized by containing 0.1 to 50% by weight based on the total weight of the dermatological pharmaceutical composition.

상기 약학 조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제 제형을 포함한다. The pharmaceutical composition includes a cream, a gel, a patch, a spray, an ointment, an alarm, a lotion, a liniment, a pasta or a cataplasmal formulation.

또한, 상기 목적을 달성하기 위하여, 본 발명은 복분자 씨 추출물을 유효성분으로 함유하는 미백 및 피부노화 개선 및 예방용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for improving and preventing whitening and skin aging comprising an extract of bokbunja as an active ingredient.

또한, 상기 화장료 조성물은 화장수, 스킨, 로션, 영양로션, 영양크림, 마사지 크림, 에센스, 팩의 제형을 포함한다.In addition, the cosmetic composition includes formulations of lotion, skin, lotion, nutrition lotion, nutritional cream, massage cream, essence, and pack.

본원에서 정의되는 복분자 씨 추출물은 물, 탄소수 1 내지 4의 저급알코올, 아세톤, 또는 이들의 혼합용매, 바람직하게는, 물, 에탄올, 아세톤 또는 이들의 혼합용매, 보다 바람직하게, 물 및 에탄올 혼합용매, 보다 더 바람직하게는 30 내지 90% 물 및 에탄올 혼합용매에 추출 가능한 추출물; 구체적으로, 건조 복분자 씨를 세척 후 물, 탄소수 1 내지 4의 저급알코올, 아세톤, 또는 이들의 혼합용매, 바람직하게는, 물, 메탄올, 에탄올 또는 이들의 혼합용매, 보다 바람직하게는, 물 및 에탄올 혼합용매, 보다 더 바람직하게는 30 내지 90% 물 및 에탄올 혼합용매를 가하여 0℃ 내지 150℃, 바람직하게는 20℃ 내지 100℃의 온도에서 30분내지 72시간, 바람직하게는 12시간 내지 48시간 동안 초음파 추출법, 열수 추출법, 상온 추출법 또는 환류추출법, 바람직하게는 상온 추출법을 약 1 내지 20회, 바람직하게는 2 내지 10회 반복 수행하여 얻은 추출액을 여과, 감압 농축, 및 건조하는 단계를 통하여 수득한 추출물을 포함한다.The bramble seed extract as defined herein is prepared by mixing water, a lower alcohol having 1 to 4 carbon atoms, acetone or a mixed solvent thereof, preferably water, ethanol, acetone or a mixed solvent thereof, more preferably water and an ethanol mixed solvent , Even more preferably from 30 to 90% water and ethanol mixed solvent; Specifically, the washed rice bran seeds are washed and then washed with water, a lower alcohol having 1 to 4 carbon atoms, acetone, or a mixed solvent thereof, preferably water, methanol, ethanol or a mixed solvent thereof, more preferably water and an ethanol mixture More preferably 30 to 90% water and ethanol mixed solvent at a temperature of 0 ° C to 150 ° C, preferably 20 ° C to 100 ° C for 30 minutes to 72 hours, preferably 12 hours to 48 hours The extract obtained by repeatedly performing the ultrasonic extraction method, the hot water extraction method, the room temperature extraction method or the reflux extraction method, preferably the room temperature extraction method, about 1 to 20 times, preferably 2 to 10 times, is subjected to filtration, ≪ / RTI >

상기 제조방법으로 제조된 추출물은 티로시나제 (Tyrosinase) 효소 저해 활성, 엘라스타제 (Elastase) 효소 저해활성, 세포 티로시나제 (celluar tyrosinase) 효소 저해활성, 멜라닌(melanin) 생합성 저해활성, 프로-콜라겐 (Pro-collagen) 생합성 저해 활성 등이 탁월함을 확인함으로써, 상기 조성물을 미백 및 피부노화의 예방 및 치료용 피부외용 약학조성물 또는 화장료 조성물로 유용함을 확인하였다. The extract prepared by the above-mentioned method can be used as an agent for inhibiting tyrosinase enzyme activity, Elastase enzyme inhibitory activity, celluli tyrosinase enzyme inhibitory activity, melanin biosynthesis inhibitory activity, pro- collagen and biosynthesis inhibitory activity, it was confirmed that the composition is useful as an external dermatological pharmaceutical composition or cosmetic composition for preventing and treating whitening and skin aging.

상기 추출물은 피부외용 약학조성물은 총 중량에 대하여 0.1 내지 50 중량%으로 포함함을 특징으로 한다.The extract of the present invention is characterized by containing 0.1 to 50% by weight based on the total weight of the dermatological pharmaceutical composition.

상기 약학 조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제 제형을 포함한다. The pharmaceutical composition includes a cream, a gel, a patch, a spray, an ointment, an alarm, a lotion, a liniment, a pasta or a cataplasmal formulation.

또한, 상기 화장료 조성물은 화장수, 스킨, 로션, 영양로션, 영양크림, 마사지 크림, 에센스, 팩의 제형을 포함한다.In addition, the cosmetic composition includes formulations of lotion, skin, lotion, nutrition lotion, nutritional cream, massage cream, essence, and pack.

따라서 본원 발명은 하기 제조방법 및 상기 제조방법으로 수득된 추출물을 유효성분으로 함유하는 미백 및 피부노화 치료 및 예방용 피부외용 약학 조성물 및 화장료 조성물을 제공한다.
Accordingly, the present invention provides an external dermatological pharmaceutical composition and a cosmetic composition for the treatment and prevention of whitening and skin aging, which comprises the following production method and the extract obtained by the production method as an active ingredient.

또한, 본 발명의 복분자 씨는 오랫동안 생약 및 식용으로 사용되어 오던 식품으로서 이들로부터 추출된 본 발명의 추출물 역시 독성 및 부작용 등의 문제가 없으며, 피부 첩포 시험에서 무자극 시료임이 입증되었으므로 장기간 사용 시에도 안심하고 사용할 수 있다.
In addition, the brambly seed of the present invention has been used for a long period of herbal medicine and food, and the extract of the present invention extracted therefrom has no problems such as toxicity and side effects and has proved to be a non-irritant sample in the skin patch test. Can be used with confidence.

본 발명의 추출물을 함유하는 피부외용 약학조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 형태의 약학조성물로 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. The dermatological pharmaceutical composition containing the extract of the present invention can be used as a pharmaceutical composition in the form of external preparation for skin such as cream, gel, patch, spray, ointment, warning agent, lotion, liniment, pasta or cataplasma However, the present invention is not limited thereto.

본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 ㎎/㎏으로, 바람직하게는 0.001 내지 10 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at a daily dose of 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

본 발명의 추출물은 미백 및 피부노화 방지 효과를 갖는 화장품 및 세안제 등에 다양하게 이용될 수 있다.The extract of the present invention can be used variously in cosmetics and cleansers having a whitening and anti-aging effect.

본 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 화장수, 스킨, 로션, 영양로션, 영양크림, 맛사지크림, 에센스, 팩 등과 같은 화장품류와 클렌징, 세안제, 비누, 트리트먼트, 미용액 등이 있다.Examples of products to which the present composition can be added include cosmetics such as lotion, skin, lotion, nutrition lotion, nutritional cream, massage cream, essence, pack, cleansing, cleanser, soap, have.

본 발명의 화장료는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다.The cosmetic composition of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

수용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염 (티아민염산염, 아스코르빈산나트륨염 등)이나 유도체 (아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다.The water-soluble vitamin is not particularly limited as long as it can be compounded in cosmetics. Preferably, vitamin B, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, And their salts (thiamine hydrochloride, sodium ascorbate, etc.) or derivatives (sodium ascorbic acid-2-phosphate, magnesium ascorbate-2-phosphate etc.) can also be added to water-soluble vitamins . The water-soluble vitamin can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzymatic method, or a chemical synthesis method.

유용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (d1-알파 토코페롤, d-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체 (팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산 dl-알파 토코페롤, 니코틴산 dl-알파 토코페롤비타민 E, dl-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함된다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다.Usable vitamins include vitamins such as vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol) , Derivatives thereof (such as palmitic acid ascorbin, stearic acid ascorbic acid, dipalmitic acid ascorbin, dl-alpha tocopherol acetic acid, dl-alpha tocopherol nicotinic acid vitamin E, dl-pantothenyl alcohol, D-pantothenyl alcohol, Ether, etc.) are also included in the usable vitamins used in the present invention. Usability Vitamins can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzyme or a chemical synthesis method.

고분자 펩티드로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 고분자 펩티드는 미생물의 배양액으로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymeric peptide may be any compound as long as it can be compounded in cosmetics, and examples thereof include collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, and keratin. The polymeric peptide can be obtained by a conventional method such as purification from a culture broth of a microorganism, an enzymatic method, or a chemical synthesis method, or it can be purified from natural products such as ducks such as pigs and cows and silk fiber of silkworms.

고분자 다당으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 히알루론산나트륨, 콘드로이틴 황산 또는 그 염 (나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다.The polymeric polysaccharide may be any compound as long as it can be incorporated in cosmetics, and examples thereof include hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.). For example, chondroitin sulfate or a salt thereof can be usually purified from mammals or fish.

스핑고 지질로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 세라미드, 피토스핑고신, 스핑고당지질 등을 들 수 있다. 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다.Sphingo lipids may be any as long as they can be incorporated into cosmetics, and preferable examples thereof include ceramides, phytosphingosine and sphingoglycolipids. Sphingoid lipids can be purified from ordinary mammals, fish, shellfish, yeast or plants by conventional methods or can be obtained by chemical synthesis.

해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다.The seaweed extract may be any of those which can be compounded in cosmetics. Preferably, the seaweed extract is selected from the group consisting of algae extract, red pepper extract, green algae extract and the like. Also, the algae extract may be colored guanine, arginic acid, Potassium alginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained from seaweed by a conventional method.

본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다.The cosmetic of the present invention may be blended with other essential ingredients, if necessary, in combination with the essential ingredients.

이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.

유지 성분으로서는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the oil retaining component include ester-based oil retaining, hydrocarbon-based oil retaining, silicone-based oil retaining, fluoric oil retaining, animal retention and plant retention.

에스테르계 유지로서는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디(카프릴,카프린산)프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.Examples of ester-based fats include glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isostearyl isostearate, Butyl isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, butyl, ethyl linoleate, isopropyl linoleate, ethyl oleate, isosilyl myristate, isostearic acid isostearyl, isostearyl palmitate, octyldodecyl myristate, Trimethylol propane, triisostearic acid trimethylol propane, tetra 2-ethylhexanoic acid pentaerythritol tetra (2-ethylhexanoate) , Decyl caprylate, decyl laurate, hexyl laurate, myristate decyl, myristyl myristate, myristine monoethyl stearate, stearyl stearate, decyl oleate, ricinoleic acid tri , Isostearyl stearate, isostearyl stearate, isodecyl stearate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, isopropyl stearate, isopropyl stearate, isopropyl stearate, -Hexyl stearate, stearyl ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, di (capryl, capric acid) propylene glycol, Propyleneglycol propionate, propyleneglycol propionate, dicaproic acid neopentyl glycol, dioctanoic acid neopentyl glycol, tricarboxylic acid glyceryl, triunsaturated glyceryl, triisopalmitic acid glyceryl, triisostearic acid glyceryl, neopentanoic acid octyldodecyl Octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, Octyldecyl lactate, octyldecyl lactate, octyldecyl lactate, polyglycerin oleic acid ester, polyglycerin isostearic acid ester, triisocetyl citrate, triisobutyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, But are not limited to, ethyl, acetyltriethyl citrate, acetyltributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di-2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, But are not limited to, dioctyl sebacate, stearic acid cholesteryl, isostearic acid cholesteryl, hydroxystearic acid cholesteryl, oleic acid cholesteryl, oleic acid dihydrocholesteryl, isostearic acid pitostearyl, Stearoyl hydroxystearic acid isostearyl, 12-stearoyl stearyl hydroxystearate, 12-stearo And monohydroxystearic acid and esters such as sostearyl.

탄화 수소계 유지로서는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로크리스탈린왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Examples of the hydrocarbon hydrocarbon-based fats include hydrocarbon fats and oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, floating isoparaffin, polybutene, microcrystalline wax and vaseline.

실리콘계 유지로서는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산ㆍ메틸세틸옥시실록산 공중합체, 디메틸실록산ㆍ메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.Examples of silicone based oils include polymethyl silicone, methylphenyl silicone, methyl cyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane-methylcetyloxysiloxane copolymer, dimethylsiloxane-methylstarchoxysiloxane copolymer, alkyl Modified silicone oils, and amino-modified silicone oils.

불소계 유지로서는 퍼플루오로폴리에테르 등을 들 수 있다.Examples of the fluorine-based oil include perfluoropolyether and the like.

동물 또는 식물 유지로서는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 새플라워유, 대두유, 옥수수유, 유채유, 행인(杏仁)유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 메도홈유, 난황유, 우지(牛脂), 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀린, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.Examples of animal or vegetable oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, new flower oil, soybean oil, corn oil, rape oil, apricot kernel oil, palm kernel oil, palm oil, castor oil, , Corn oil, palm oil, palm oil, cucumber nut oil, wheat germ oil, rice germ oil, shea butter, coltsfoot colostrum, marker daisy nut oil, mead home oil, egg oil, , Canned wax, carnauba wax, liquid lanolin, hardened castor oil, and the like.

보습제로서는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include water-soluble low-molecular moisturizing agents, oil-soluble molecular moisturizing agents, water-soluble polymers, and oil-soluble polymers.

수용성 저분자 보습제로서는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.Examples of the water-soluble low-molecular moisturizing agent include serine, glutamine, sorbitol, mannitol, sodium pyrrolidone-carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B Glycol (polymerization degree n = 2 or more), polyglycerin B (polymerization degree n = 2 or more), lactic acid, lactic acid salt and the like.

지용성 저분자 보습제로서는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the lipid-soluble low-molecular moisturizing agent include cholesterol and cholesterol ester.

수용성 고분자로서는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성 키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyaspartic acid, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, dextrin, etc. .

지용성 고분자로서는 폴리비닐피롤리돈ㆍ에이코센 공중합체, 폴리비닐피롤리돈ㆍ헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다.Examples of the oil-soluble polymer include polyvinylpyrrolidone / eicosene copolymer, polyvinylpyrrolidone / hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, and polymer silicone.

에몰리엔트제로서는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollients include long chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid and lanolin fatty acid cholesteryl ester.

계면 활성제로서는 비이온성 계면 활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제 등을 들 수 있다.Examples of the surfactant include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants.

비이온성 계면 활성제로서는 자기 유화형 모노스테아르산글리세린, 프로필렌글리콜지방산에스테르, 글리세린지방산에스테르, 폴리글리세린지방산에스테르, 솔비탄지방산에스테르, POE (폴리옥시에틸렌)솔비탄지방산에스테르, POE 솔비트지방산에스테르, POE 글리세린지방산에스테르, POE 알킬에테르, POE 지방산에스테르, POE 경화피마자유, POE 피마자유, POEㆍPOP (폴리옥시에틸렌ㆍ폴리옥시프로필렌) 공중합체, POEㆍPOP 알킬에테르, 폴리에테르변성실리콘, 라우린산알카놀아미드, 알킬아민옥시드, 수소첨가대두인지질 등을 들 수 있다.Examples of the nonionic surfactant include self emulsifying monostearate glycerin, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbit fatty acid ester, POE (Polyoxyethylene / polyoxypropylene) copolymer, POE.POP alkyl ether, polyether-modified silicone, polyether-modified silicone, polyoxyethylene-polyoxypropylene (POE) Alkanolamides, alkylamine oxides, hydrogenated soybean phospholipids, and the like.

음이온성 계면 활성제로서는 지방산비누, 알파-아실술폰산염, 알킬술폰산염, 알킬알릴술폰산염, 알킬나프탈렌술폰산염, 알킬황산염, POE 알킬에테르황산염, 알킬아미드황산염, 알킬인산염, POE 알킬인삼염, 알킬아미드인산염, 알킬로일알킬타우린염, N-아실아미노산염, POE 알킬에테르카르복실산염, 알킬술포숙신산염, 알킬술포아세트산나트륨, 아실화 가수분해 콜라겐펩티드염, 퍼플루오로알킬인산에스테르 등을 들 수 있다.Examples of the anionic surfactant include fatty acid soap, alpha-acylsulfonate, alkylsulfonate, alkylarylsulfonate, alkylnaphthalenesulfonate, alkylsulfate, POE alkyl ether sulfate, alkylamide sulfate, alkyl phosphate, POE alkyl ginseng salt, Alkylsulfosuccinic acid salts, acylated hydrolyzed collagen peptide salts, and perfluoroalkyl phosphoric acid esters, and the like can be mentioned. have.

양이온성 계면 활성제로서는 염화알킬트리메틸암모늄, 염화스테아릴트리메틸암모늄, 브롬화스테아릴트리메틸암모늄, 염화세토스테아릴트리메틸암모늄, 염화디스테아릴디메틸암모늄, 염화스테아릴디메틸벤질암모늄, 브롬화베헤닐트리메틸암모늄, 염화벤잘코늄, 스테아르산디에틸아미노에틸아미드, 스테아르산디메틸아미노프로필아미드, 라놀린 유도체 제 4급 암모늄염 등을 들 수 있다.Examples of the cationic surfactant include alkyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, cetostearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium chloride, behenyl trimethyl ammonium chloride, Benzalkonium, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salts of lanolin derivatives, and the like.

양성 계면 활성제로서는 카르복시베타인형, 아미드베타인형, 술포베타인형, 히드록시술포베타인형, 아미드술포베타인형, 포스포베타인형, 아미노카르복실산염형, 이미다졸린 유도체형, 아미드아민형 등의 양성 계면 활성제 등을 들 수 있다.Examples of the amphoteric surfactant include carboxybetaine type, amide betaine type, sulfobetaine type, hydroxysulfobetaine type, amidosulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type and amide amine type Amphoteric surfactants and the like.

유기 및 무기 안료로서는 규산, 무수규산, 규산마그네슘, 탤크, 세리사이트, 마이카, 카올린, 벵갈라, 클레이, 벤토나이트, 티탄피막운모, 옥시염화비스무트, 산화지르코늄, 산화마그네슘, 산화아연, 산화티탄, 산화알루미늄, 황산칼슘, 황산바륨, 황산마그네슘, 탄산칼슘, 탄산마그네슘, 산화철, 군청, 산화크롬, 수산화크롬, 칼라민 및 이들의 복합체등의 무기 안료 ; 폴리아미드, 폴리에스테르, 폴리프로필렌, 폴리스티렌, 폴리우레탄, 비닐수지, 요소수지, 페놀수지, 불소수지, 규소수지, 아크릴수지, 멜라민수지, 에폭시수지, 폴리카보네이트수지, 디비닐벤젠ㆍ스티렌 공중합체, 실크파우더, 셀룰로오스, CI 피그먼트옐로우, CI 피그먼트오렌지 등의 유기 안료 및 이들의 무기 안료와 유기 안료의 복합 안료 등을 들 수 있다.Examples of the organic and inorganic pigments include inorganic pigments such as silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, Bengala, clay, bentonite, titanium mica, titanium oxide, bismuth chloride, zirconium oxide, magnesium oxide, Inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, chromium oxide, chromium oxide, chromium hydroxide, But are not limited to, polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluororesin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, Silk powder, cellulose, CI Pigment Yellow, CI Pigment Orange, and composite pigments of inorganic pigments and organic pigments thereof.

유기 분체로서는 스테아르산칼슘 등의 금속비누 ; 세틸린산아연나트륨, 라우릴린산아연, 라우릴린산칼슘 등의 알킬인산금속염 ; N-라우로일-베타-알라닌칼슘, N-라우로일-베타-알라닌아연, N-라우로일글리신칼슘 등의 아실아미노산 다가금속염 ; N-라우로일-타우린칼슘, N-팔미토일-타우린칼슘 등의 아미드술폰산 다가금속염 ; N-엡실론-라우로일-L-리진, N-엡실론-팔미토일리진, N-알파-파리토일올니틴, N-알파-라우로일아르기닌, N-알파-경화우지지방산아실아르기닌 등의 N-아실염기성아미노산 ; N-라우로일글리실글리신 등의 N-아실폴리펩티드 ; 알파-아미노카프릴산, 알파-아미노라우린산 등의 알파-아미노지방산 ; 폴리에틸렌, 폴리프로필렌, 나일론, 폴리메틸메타크릴레이트, 폴리스티렌, 디비닐벤젠ㆍ스티렌 공중합체, 사불화에틸렌 등을 들 수 있다.As the organic powder, metallic soap such as calcium stearate; Metal salts of alkyl phosphates such as sodium zinc cetylate, zinc laurylate and calcium lauryl laurate; Acylamino acid polyvalent metal salts such as N-lauroyl-beta-alanine calcium, N-lauroyl-beta-alanine zinc and N-lauroylglycine calcium; Amidosulfonic acid multivalent metal salts such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; Such as N-epsilon-lauroyl-L-lysine, N-epsilon-palmitoylidene, N-alpha-paratyylnitine, N-alpha-lauroyl arginine, Acyl basic amino acids; N-acylpolypeptides such as N-lauroylglycylglycine; Alpha-amino fatty acids such as alpha-aminocaprylic acid, alpha-aminoaurauric acid, and the like; Polyethylene, polypropylene, nylon, polymethylmethacrylate, polystyrene, divinylbenzene-styrene copolymer, ethylene tetrafluoride, and the like.

자외선 흡수제로서는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of ultraviolet absorbers include paraaminobenzoic acid, ethyl parnamobenzoate, amyl paranobenzoate, octyl paranobenzoate, ethyleneglycol salicylate, phenyl salicylate, benzyl salicylate, benzyl salicylate, butylphenyl salicylate, homomenthyl salicylate, benzyl cinnamate , Octyl methoxycinnamate, dioctyl methoxycinnamate, mono-2-ethylhexane glyceryl dipyrromethoxycinnamate, isopropyl paratumoxycinnamate, diisopropyl-diisopropyl cinnamate ester mixture, Carninoic acid, ethyl urocanoate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and salts thereof, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxybenzophenone , Tetrahydroxybenzophenone, 4- tert -butyl-4'-methoxydibenzoylmethane, 2,4,6-trianylino- p- (carbo-2'-ethylhexyl-1'- , 3,5-triazine, 2- (2- And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.

살균제로서는 히노키티올, 트리클로산, 트리클로로히드록시디페닐에테르, 크로르헥시딘글루콘산염, 페녹시에탄올, 레조르신, 이소프로필메틸페놀, 아줄렌, 살리칠산, 진크필리티온, 염화벤잘코늄, 감광소 301 호, 모노니트로과이어콜나트륨, 운데시렌산 등을 들 수 있다.Examples of the disinfectant include hinokitiol, trichloroacid, trichlorohydroxydiphenyl ether, crohexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, zinc filitione, benzalkonium chloride, No. 301, mononitro and eicol sodium, and undecylenic acid.

산화 방지제로서는 부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산 등을 들 수 있다.Examples of the antioxidant include butylhydroxyanisole, gallic acid propyl, and eicosorbic acid.

pH 조정제로서는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate and the like.

알코올로서는 세틸알코올 등의 고급 알코올을 들 수 있다.Examples of the alcohol include higher alcohols such as cetyl alcohol.

또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총중량에 대하여 바람직하게는 0.01 - 5 % 중량, 보다 바람직하게는 0.01 - 3 % 중량로 배합된다.In addition, any of the above components may be blended within the range not to impair the objects and effects of the present invention, but it is preferably 0.01 to 5% by weight based on the total weight, Preferably 0.01 to 3% by weight.

본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture or the like.

본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 화합물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다.The ingredients contained in the cosmetic composition of the present invention may contain, as an active ingredient, the ingredients conventionally used in cosmetic compositions in addition to the above-mentioned compounds, for example, conventional additives such as stabilizers, solubilizers, vitamins, And a carrier.

본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다.The cosmetic composition of the present invention can be prepared into any formulation conventionally produced in the art, and examples thereof include emulsions, creams, lotions, packs, foundations, lotions, essences, and hair cosmetics.

구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다.Specifically, the cosmetic composition of the present invention can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, a moisturizing cream, a hand cream, Packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.

본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

상기에 언급한 바와 같이, 본 발명의 복분자 씨 추출물은 티로시나제 (Tyrosinase) 효소 저해 활성, 엘라스타제 (Elastase) 효소 저해활성, 세포 티로시나제 (celluar tyrosinase) 효소 저해활성, 멜라닌(melanin) 생합성 저해활성, 프로-콜라겐 (Pro-collagen) 생합성 저해 활성 등이 탁월함을 확인함으로써, 상기 조성물은 미백 및 피부노화의 예방 및 치료용 피부외용 약학조성물 또는 화장료 조성물로 유용하다.
As described above, the brambler seed extract of the present invention is useful as an inhibitor of tyrosinase enzyme activity, an enzyme activity inhibiting activity, a cellulase tyrosinase enzyme inhibition activity, a melanin biosynthesis inhibiting activity, Pro-collagen biosynthesis inhibitory activity and the like, the composition is useful as an external dermatological pharmaceutical composition or cosmetic composition for preventing and treating whitening and skin aging.

도 1는 복분자 씨 추출물의 마우스흑색세포종과 휴먼섬유아세포의 세포생존율을 나타낸 도이며(결과는 3중치의 평균(means) ± S.D.으로 표시함);
도 2는 복분자 씨 추출물의 버섯 티로시나제 저해활성을 나타낸 도이며(결과는 3중치의 평균(means) ± S.D.으로 표시함);
도 3는 복분자 씨 추출물의 B16F10 세포 티로시나제 저해활성을 나타낸 도이며(결과는 3중치의 평균(means) ± S.D.으로 표시함);
도 4는 복분자 씨 추출물의 B16F10 세포 티로시나제 멜라닌 양에 미치는 영향을 나타낸 도이며(결과는 3중치의 평균(means) ± S.D.으로 표시함);
도 5는 복분자 씨 추출물의 엘라스타제 저해활성을 나타낸 도이며(결과는 3중치의 평균(means) ± S.D.으로 표시함);
도 6는 복분자 씨 추출물의 엘라스타제에 대한 프로-콜라겐 생합성에 미치는 영향을 나타낸 도이다(결과는 3중치의 평균(means) ± S.D.으로 표시함).
Brief Description of the Drawings Fig. 1 is a graph showing the cell survival rate of mouse melanoma cell and human fibroblast of bokbunja seed extract (the results are expressed as mean (SD) means ± SD);
Fig. 2 is a graph showing the mushroom tyrosinase inhibitory activity of the bokbunja seed extract (the results are expressed as means (mean) ± SD of triplicate);
Fig. 3 is a graph showing B16F10 cytotoxic inhibitory activity of bokbunja seed extract (the results are expressed as mean (mean) SD of triplicate);
FIG. 4 is a graph showing the effect of bramblymus cereus extract on the amount of B16F10 cell tyrosinase melanin (the results are expressed as means (mean) ± SD of triplicate);
Fig. 5 is a graph showing the inhibitory activity of Rubus coreanus extract on elastase (the results are expressed as mean (mean) SD of triplicate);
Fig. 6 is a graph showing the effect of bokbunja seed extract on pro-collagen biosynthesis to elastase (the results are expressed as mean (mean) SD of triplicate values).

이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples.

단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예, 참고예 및 실험예에 의해 한정되는 것은 아니다.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following Examples, Reference Examples and Experimental Examples.

실시예 Example 1. 복분자 씨 추출물의 제조1. Preparation of Bokbunja Seed Extract

건조 상태의 복분자 씨 100g (Rubus coreanus M. Seed, 경북 김천시 부항면 해인리)에 70% 에탄올을 시료 중량의 10배 양을 가하여 실온에서 24시간 침지하여 상징액과 침전물을 분리하여 동일한 방법으로 3회 반복 추출하였다. 각 추출물들은 원심분리 및 여과(filter paper; Whatman No. 2), 농축 후 동결 건조하여 복분자씨 에탄올 추출물(3.52g)을 얻었다. (이하 RC70E라 함)를 획득하였다. 이를 냉장실에 보관하면서 본 실험의 시료로 사용하였다.
Dried bramble seeds 100g ( Rubus coreanus M. Seed, Heinlee, Gimcheon City, Gyeongbuk), and the supernatant and precipitate were separated from the supernatant by repeating the same procedure three times. Each extract was centrifuged and filtered (filter paper; Whatman No. 2), concentrated and lyophilized to give 3.52 g of brambly seed ethanol extract. (Hereinafter referred to as RC70E). This was used as a sample of this experiment while being stored in a refrigerator room.

참고예Reference example 1. 실험 준비 1. Experimental preparation

1-1. 미백 및 주름억제 효과 측정 시약1-1. Whitening and anti-wrinkle effect measuring reagent

미백 및 주름억제 효과 측정에 사용된 시약인 mushroom tyrosinase Sigma Chemical Co. (St, Louis, MO, USA), L- 3,4-dihydroxyphenyl-alanine Sigma Chemical Co. (St, Louis, MO, USA), L-DOPA), porcine pancreas elastase Sigma Chemical Co. (St, Louis, MO, USA), PPE), Aster glehni -succinyl-(L-Ala)3-Aster glehni -nitroanilide Sigma Chemical Co. (St, Louis, MO, USA), collagenase Sigma Chemical Co. (St, Louis, MO, USA) 및 4-phenylazo benzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg Sigma Chemical Co. (St, Louis, MO, USA) 등을 구입하여 사용하였다.
The mushroom tyrosinase, a reagent used for measuring whitening and wrinkle suppressing effect, was purchased from Sigma Chemical Co. (St. Louis, Mo., USA), L-3,4-dihydroxyphenyl-alanine Sigma Chemical Co. (St, Louis, MO, USA), L-DOPA), porcine pancreas elastase. (St, Louis, MO, USA), PPE), Aster glehni-succinyl- (L-Ala) 3-Aster glehni-nitroanilide Sigma Chemical Co. (St, Louis, Mo., USA), collagenase Sigma Chemical Co. (St, Louis, MO, USA) and 4-phenylazo benzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg. (St, Louis, MO, USA) were purchased and used.

1-2. 실험에 사용된 기기1-2. Devices used in experiments

생리활성 실험에 사용된 기기는 UV/VIS spectrophotometer (UVD-3200, Hitachi, Japan), rotary vacuum evaporator (R-215V, Tokyo, Rikakikai Co. Japan), centri-fuge (Sorvall, Hitachi, Japan), freeze drier(FD5508, Ilsin, Korea), microscope (Nikon Eclipse Ti-U, Nikon, Japan), CO2 incubator (SANYO MCO 20AIC, Hanbaek Scientific Co. Korea), pH meter (Brinkmann 632, Metrohm, Switzerland), BOD incubator (LTI-1000SD, Hanbaek Co. Korea), autoclave (HB-506, Hanbaek Scientific Co. Korea), ELISA reader(VersaMax, Bio Rad, Japan)를 사용하였다.
The instrument used for the physiological activity experiments was a UV / VIS spectrophotometer (UVD-3200, Hitachi, Japan), a rotary vacuum evaporator (R-215V, Tokyo, Rikakikai Co.), a centri-fuge (Sorvall, Hitachi, Japan) BOD incubator (Brinkmann 632, Metrohm, Switzerland), CO2 incubator (SANYO MCO 20AIC, Hanbaek Scientific Co. Korea), pH meter (Brinkmann 632, Metrohm, Switzerland), microscope (Nikon Eclipse Ti-U, Nikon, Japan) LTI-1000SD, Hanbaek Co. Korea), autoclave (HB-506, Hanbaek Scientific Co. Korea) and ELISA reader (VersaMax, Bio Rad, Japan).

1-3. 세포배양1-3. Cell culture

본 실험에 이용한 각 세포의 배양은 10% fetal bovine serum(FBS)과 1% penicillin/streptomycin(100U/mL)을 첨가한 Dulbeco's modified eagle ‘s medium (New York, USA DMEM) 배지를 사용하였으며, 37℃, 5% CO2 배양기(incubator)에 적응시켜 계대 배양하였다.
The cells were cultured in Dulbeco's modified eagle's medium (New York, USA DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin (100 U / , Incubated in a 5% CO2 incubator and subcultured.

실험예Experimental Example 1.  One. MTTMTT assayassay 에 의한 세포 생존율 측정Of cell survival

실시예에서 얻은 시료들의 MTT assay에 의한 세포 생존율을 시험하기 위하여 문헌에 개시된 Carmichael의 방법[Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB. (1987) Evaluation of a tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47(4), 936-942.]을 응용하여 하기와 같이 실험하였다To test the cell survival rate by MTT assay of the samples obtained in the examples, the method of Carmichael disclosed in the document [Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB. (1987) Evaluation of a tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res . 47 (4), 936-942.

각 세포주[melanoma(B16F10, ATCC), fibroblast(CCRF S-180 , ATCC), macrophage(Raw 264.7) cell, ATCC]을 96 well plate에 0.6~8×103cells/well이 되게 0.18mL 분주하고, 시료를 농도 별로 조제하여 0.02mL 첨가한 후 37℃, 5% CO2 배양기에서 24시간 배양하였다. Each cell line (melanoma (B16F10, ATCC), fibroblast (CCRF S-180, ATCC), macrophage (Raw 264.7) cell and ATCC) was dispensed in a 96 well plate at a concentration of 0.6 to 8 × 10 3 cells / 0.02 mL was added, and the cells were cultured in a 5% CO 2 incubator at 37 ° C for 24 hours.

대조군은 시료와 동량의 증류수를 첨가하여 동일한 조건으로 배양하였다. 여기에 5mg/mL 농도로 제조한 MTT 용액 0.02mL를 첨가하여 4시간 배양한 후 배양액을 제거하고 각 well당 DMSO:Ethanol(1:1) 0.15mL를 가하여 실온에서 30분간 반응 시킨 뒤 ELISA reader로 550nm에서 흡광도를 측정하였다. 세포 생존율 측정은 시료용액의 첨가군와 무첨가군의 흡광도 감소율로 나타내었다. In the control group, the same amount of distilled water as that of the sample was added and the cells were cultured under the same conditions. After adding 0.02 mL of the MTT solution prepared at a concentration of 5 mg / mL for 4 hours, the culture solution was removed, and 0.15 mL of DMSO: Ethanol (1: 1) was added to each well and reacted at room temperature for 30 minutes. Absorbance was measured at 550 nm. The cell viability was measured by the absorbance reduction rate of the sample solution addition group and the no addition group.

본 실험 결과, 마우스 흑색 세포와 휴먼섬유아세포 에서의 복분자 추출물의 1, 10, 25, 50, 100 μg/ml의 농도에서 세포생존율을 측정한 결과는 도 1)과 같이 나타내었다. 복분자 추출물의 농도별로 마우스 흑색세포와 휴먼섬유아세포에서 각각 측정한 결과 마우스 흑색세포의 경우 99, 92, 74, 56, 42%의 세포 생존율을, 섬유아세포의 경우 95, 90, 65, 62, 58%로 각각 나타내었다. 이와 같은 결과로 복분자씨는 두 세포에서 25, 50, 100 μg/ml의 농도에대해 약한 독성을 나타내는 것을 확인 하여 하기에 실험은 모두 세포 생존율이 높은 1, 10 μg/ml의 농도에서 측정하였다.
As a result, cell viability was measured at the concentrations of 1, 10, 25, 50, and 100 μg / ml of the bokbunja extract in mouse melanocytes and human fibroblasts, as shown in FIG. The cell viability of mouse melanocytes was 99, 92, 74, 56 and 42%, and that of fibroblasts was 95, 90, 65, 62, and 58%, respectively, as measured by mouse melanocytes and human fibroblasts %, Respectively. As a result, it was confirmed that brambled seeds showed weak toxicity at 25, 50 and 100 μg / ml in both cells, and the experiments were carried out at concentrations of 1 and 10 μg / ml, which are high cell survival rates.

실험예Experimental Example 2. 미백 활성 실험 2. Whitening activity experiment

1-1. 1-1. 티로시나제Tyrosinase 저해활성 Inhibitory activity

실시예에서 얻은 시료들의 티로시나제 (Tyrosinase) 저해활성을 시험하기 위하여 문헌에 개시된 Yagi 등의 방법을 응용하여 하기와 같이 실험하였다 [Yagi A, Kanbara T and Morinobu N. (1986) The effect of tyrosinase inhibition for aloe. Planta Media. 3981, 517-519.]In order to test the tyrosinase inhibitory activity of the samples obtained in the examples, Yagi et al. (Yagi A, Kanbara T and Morinobu N. (1986) applied the method of Yagi et al. aloe Planta Media . 3981, 517-519.]

반응구는 0.175M sodium phosphate buffer(pH 6.8) 0.5mL에 10mM L-DOPA를 녹인 기질액 0.2mL 및 시료용액 0.1mL의 혼합액에 버섯 티로시나제 (mushroom tyrosinase; 110U/mL) 0.2mL을 첨가하여 25℃에서 2분간 반응시켜 반응액 중에 생성된 DOPA chrome을 475nm에서 측정하였다. 티로시나제 (Tyrosinase) 저해활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.To the reaction mixture, 0.2 mL of mushroom tyrosinase (110 U / mL) was added to a mixture of 0.2 mL of the substrate solution in which 10 mM L-DOPA was dissolved in 0.5 mL of 0.175 M sodium phosphate buffer (pH 6.8) and 0.1 mL of the sample solution, DOPA chrome produced in the reaction solution was measured at 475 nm for 2 minutes. The tyrosinase inhibitory activity was expressed by the absorbance reduction rate of the sample solution and the non-added sample.

본 실험 결과, 피부 내에서 멜라닌 중합체 생합성을 효과적으로 저해할 수 있는 티로시나제 저해활성을 측정하기 위하여 버섯(mushroom) 유래의 티로시나제 저해활성 측정 결과는 도 2과 같이 나타내었다. 본 실험에서는 복분자 씨앗 추출물을 10, 100, 1000 μg/ml의 농도로 버섯(mushroom) 유래의 티로시나제 효소와 반응을 시킨 결과 41%, 49%, 52%로 저해능을 나타내었다.
As a result of the present experiment, the result of measurement of tyrosinase inhibitory activity from mushroom to measure tyrosinase inhibitory activity which can effectively inhibit melanin polymer biosynthesis in the skin is shown in FIG. In this experiment, the bacterium seed extract was reacted with mushroom-derived tyrosinase enzyme at a concentration of 10, 100, and 1000 μg / ml, and showed 41%, 49%, and 52%, respectively.

1-2. 1-2. 세포내Intracellular 티로시나제Tyrosinase 저해활성 Inhibitory activity

실시예에서 얻은 시료들의 세포내 티로시나제(Cellular tyrosinase) 저해활성을 시험하기 위하여 문헌에 개시된 방법을 응용하여 하기와 같이 실험하였다[Akiu S, Suzuki Y, Asahara T, Fujinuma Y and Fukuda M. (1991) Inhibitory effect of arbutin on melanogenesis-biochemical study using cultured B16 melanoma cells. Nippon Hifuka Gakkai Zasshi . 101(6), 609-613].
In order to test cellular intracellular tyrosinase inhibitory activity of the samples obtained in the examples, the following method was applied as described in the literature (Akiu S, Suzuki Y, Asahara T, Fujinuma Y and Fukuda M. (1991) Inhibitory effect of arbutin on melanogenesis-biochemical study using cultured B16 melanoma cells. Nippon Hifuka Gakkai Zasshi . 101 (6), 609-613).

Melanoma(B16F10 ATCC) 세포를 각 culture dish에 가득 키운 후, 배지를 제거하고 PBS로 세척하였다. 각 dish에 lysis buffer (67mM sodium phosphate buffer, 1% triton X-100, 0.1mM phenylmethyl sulfonyfluoride)를 100μL 첨가한 후 얼음에 방치하여 세포를 파괴시키고, 세포를 수집하여 초음파(ultra sonication)추출하였다. 이를 1시간 동안 방치한 후 12,500rpm에서 20분간 원심분리 하여 얻어진 상층액을 효소용액으로 사용하였다. 이를 67mM phosphate buffer(pH6.8)에 녹인 8.0mM의 L-DOPA 120μL와 시료용액 40μL를 96-well plate에 넣은 후, 67mM phosphate buffer (pH 6.8)에 녹인 효소용액 40μL을 첨가하여 37℃에서 30분간 배양한 후, 생성된 DOPA chrome의 양을 490nm에서 측정하였다. Melanoma (B16F10 ATCC) cells were filled in each culture dish, and the medium was removed and washed with PBS. 100 μl of lysis buffer (67 mM sodium phosphate buffer, 1% triton X-100, 0.1 mM phenylmethyl sulfonyfluoride) was added to each dish, and the cells were disrupted by being left on ice. Cells were collected and ultrasonicated. The supernatant obtained by centrifugation at 12,500 rpm for 20 minutes was used as an enzyme solution. After adding 120 μL of 8.0 mM L-DOPA dissolved in 67 mM phosphate buffer (pH 6.8) and 40 μL of the sample solution into a 96-well plate, 40 μL of the enzyme solution dissolved in 67 mM phosphate buffer (pH 6.8) After minute incubation, the amount of DOPA chrome produced was measured at 490 nm.

본 실험 결과, mushroom유래의 tyrosinase 저해 활성 측정 결과는 도 3에 나타내었다. 복분자 씨 추출물은 1, 000 μg/ml에서 61%의 저해율을 나타내었다.
As a result of this experiment, the measurement result of mushroom-derived tyrosinase inhibitory activity is shown in FIG. The brambled seed extract showed an inhibition rate of 61% at 1, 000 μg / ml.

1-3. 멜라닌(1-3. Melanin ( melaninmelanin ) 생합성 저해율) Biosynthesis inhibition rate

실시예에서 얻은 시료들의 피부 멜라노마 세포로부터의 멜라닌(melanin) 생합성 저해 활성을 시험하기 위하여 Hosoi 등의 문헌에 개시된 Melanoma cell(B16F10)에서의 멜라닌(melanin) 생합성 저해율 측정 방법을 응용하여 하기와 같이 실험하였다 [Hosoi J. Abe E, Suda T and Kuroki T. (1985) Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res. 45(4), 1474-1478].
In order to test the melanin biosynthesis inhibitory activity of skin melanoma cells of the samples obtained in the examples, a method of measuring the inhibition rate of melanin biosynthesis in Melanoma cell (B16F10) disclosed in Hosoi et al. [Hosoi J. Abe E, Suda T and Kuroki T. (1985) Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res . 45 (4), 1474-1478].

DMEM 배지로 배양된 멜라노마 세포(Melanoma cell, B16F10)를 100mm culture dish에 2×106cell/dish가 되게 분주하고 24시간 배양 후 시료를 농도별로 조제하여 2mL 첨가하고, 48시간 후에 인산완충액(pH 7.4)으로 세척하였다. 그 다음 0.25M trypsin-EDTA 용액으로 세포를 탈착한 후 수확한 세포를 1×106세포 당 1mL의 5% TCA로 처리하고, 2,500rpm으로 2회 원심분리한 후 분리된 melanin을 인산완충액으로 세척한 뒤 ether:ethanol (1:3) 1mL를 가하여 2회 원심분리 한 후 ether 1mL로 세척 건조시켰다. 건조된 melanin에 1N NaOH를 1mL 가하여 80℃에서 1시간 반응시킨 후 분광 광도계 405nm에서 흡광도를 측정하였다. 멜라닌(Melanin) 생합성 저해는 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.The melanoma cells (B16F10) cultured in DMEM medium were divided into 2 × 10 6 cells / dish in a 100 mm culture dish. After culturing for 24 hours, 2 ml of each sample was prepared and the cells were added with phosphate buffer (pH 7.4 ). After the cells were desorbed with 0.25 M trypsin-EDTA solution, the harvested cells were treated with 1 mL of 5% TCA per 1 × 10 6 cells, centrifuged twice at 2,500 rpm, and the separated melanin was washed with phosphate buffer Then, 1 mL of ether: ethanol (1: 3) was added, and the mixture was centrifuged twice. 1N NaOH was added to the dried melanin, reacted at 80 ° C for 1 hour, and the absorbance was measured at 405 nm by a spectrophotometer. The inhibition of melanin biosynthesis was expressed by the absorbance reduction ratio of the sample solution and the non-added sample.

복분자 씨 추출물을 천연 미백제로 사용하기 위하여 melanoma 세포에서의 멜라닌 생합성을 측정한 결과, 도 4과 같이 나타내었다. 복분자 씨 추출물은 1, 10 μg/ml의 농도에서 79, 42%의 멜라닌 저해 효과를 나타내었기에 우수한 천연 미백제로 사용이 가능할 것으로 사료된다.
Melanin biosynthesis in melanoma cells was measured in order to use bokbunja seed extract as a natural whitening agent, as shown in Fig. The extracts of bokbunja extract showed 79 and 42% inhibition of melanin at concentrations of 1 and 10 μg / ml, respectively.

실험예Experimental Example 3. 주름 개선 효능 실험 3. Wrinkle-improving efficacy experiment

3-1. 3-1. 엘라스타제Elastase (( ElastaseElastase ) 저해활성 측정) Inhibition activity measurement

실시예에서 얻은 시료들의 엘라스타제 (Elastase) 저해활성을 시험하기 위하여 카넬 (Cannell) 등을 응용하여 하기와 같이 실험하였다[Cannell RJP, Kellan SJ, Owsianks AM and Walker JM. (1988) Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Media. 54(1), 10-14].In order to test the elastase inhibitory activity of the samples obtained in the examples, Cannell et al. (Cannell RJP, Kellan SJ, Owsians AM and Walker JM. (1988) Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Media . 54 (1), 10-14].

기질로서 N-succinyl-(L-Ala)3-Aster glehni-nitroanilide를 사용하여 37℃에서 20분간 기질로부터 생성되는 Aster glehni -nitroanilide의 생성량을 405nm에서 측정하였다. 즉, 각 시험용액을 일정 농도가 되도록 조제하여 0.5mL씩 시험관에 취하고, 50mM tris-HCl buffer (pH 8.6)에 녹인 porcine pancreas elastase (2.5U/mL Sigma Chemical Co. (St, Louis, MO, USA)) 용액 0.5mL을 가한 후 기질로 50mM tris-HCl buffer (pH 8.6)에 녹인 N-succinyl-(L-Ala)3-Aster glehni -nitroanilide (0.5mg/mL)을 첨가하여 20분간 반응시켜 측정하였다. Elastase 저해활성은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다. N-succinyl- (L-Ala) 3-Aster glehni-nitroanilide was used as a substrate and the amount of Aster glehni-nitroanilide produced from the substrate at 37 ° C for 20 minutes was measured at 405 nm. Each test solution was prepared in a test tube at a constant concentration of 0.5 mL. The test tube was washed with porcine pancreas elastase (2.5 U / mL, Sigma Chemical Co., St. Louis, Mo., USA) dissolved in 50 mM tris-HCl buffer (pH 8.6) ) Was added and 0.5 ml of N-succinyl- (L-Ala) 3-Aster glehni-nitroanilide (0.5 mg / ml) dissolved in 50 mM tris-HCl buffer (pH 8.6) Respectively. Elastase inhibitory activity was expressed as the absorbance reduction ratio of the sample solution and the non - added sample.

본 실험 결과, 주름 생성과 관련된 엘라스타제 (elastase) 저해 활성을 측정한 결과는 도 5와 같이 나타내었다. 복분자 씨의 경우 10, 100, 1000μg/ml에서 각각 2%, 14%, 23%의 elastase 저해 효과가 나타났다. 대조군인 EGCG의 경우 1000μg/ml에서는 31%의 elastase 저해 효과를 나타냄으로 복분자 씨앗의 경우 EGCG와 유사한 저해 효과를 나타냄으로 Elstase 저해능에 효능을 나타냄을 확인할 수 있었다.
The result of measuring the elastase inhibitory activity associated with wrinkle formation is shown in FIG. In the case of bokbunja, the elastase inhibitory effect was 2%, 14% and 23% at 10, 100 and 1000 μg / ml, respectively. In the control group, EGCG showed 31% elastase inhibition effect at 1000 μg / ml, indicating that the brambled seeds had an inhibitory effect similar to EGCG and thus showed an efficacy against Elstase inhibition.

3-2. 프로-콜라겐 생합성 측정3-2. Pro-collagen biosynthesis assay

실시예에서 얻은 시료들의 프로-콜라겐(pro-collagen) 생합성에 미치는 영향을 시험하기 위하여 문헌에 기재된 방법을 응용하여 하기와 같이 실험하였다 [Kim JE. (2003) Effect of epigallocagechin-3-gallate on heat-modulated type Ⅰprocollagen, MMP-1, and TIMP-1 expression in cultured human dermal fibroblasts. Korea University. Seoul, Korea]. In order to test the effect of the samples obtained in the examples on the pro-collagen biosynthesis, the method described in the literature was applied as follows [Kim JE. (2003) Effect of epigallocatechin-3-gallate on heat-modulated type Ⅰprocollagen, MMP-1, and TIMP-1 expression in cultured human dermal fibroblasts. Korea University. Seoul, Korea].

CCD-986sk세포(ATCC)에 시료를 농도별로 처리했을 때 pro-collagen type Ⅰ의 합성양을 측정하기 위해 Procollagen Type-Ⅰ C-Peptide (PIP) EIA kit를 TAKARA Bio Inc. (Shiga, Japan)에서 구입하여 이용하였다. 96-well plate에 각 well당 1×104 cells/well세포가 되도록 심어준 후 24시간을 안정화 하였다. 이 후, 배양된 배지를 제거하고 시료 추출물을 농도별로 처리한 후 48시간을 배양하였다. 각 well로부터 상등액을 회수하여 procollagen Type-Ⅰ C-Peptide (PIP) EIA kit의 각 well에 첨가한 후, 제조사의 방법에 따라 procollagen type Ⅰ의 총 양을 측정 하였다. Procollagen Type-I C-Peptide (PIP) EIA kit was purchased from TAKARA Bio Inc. to measure the amount of pro-collagen type I synthesis when CCD-986sk cells (ATCC) (Shiga, Japan). Cells were plated at a density of 1 × 10 4 cells / well in a 96-well plate and then stabilized for 24 hours. After that, the cultured medium was removed, and the sample extracts were treated at different concentrations, followed by culturing for 48 hours. The supernatant from each well was recovered and added to each well of procollagen Type-I C-Peptide (PIP) EIA kit, and then the total amount of procollagen type I was measured according to the manufacturer's method.

본 실험 결과, 복분자 씨 추출물의 섬유아세포에 대한 procollagen type Ⅰ C-peptide(PICP) enzyme immunoassay에 의한 collagen 생합성량을 측정한 결과를 도 6와 같이 나타내었다. 복분자 씨 추출물의 경우에 1, 10 μg/ml의 농도에서 30, 58%의 효과를 나타내었으며, 이는 대조군인 EGCG와 비교시에도 비슷한 효능을 가짐을 확인할 수 있었다.
As a result, the amount of collagen biosynthesis measured by procollagen type Ⅰ C-peptide (PICP) enzyme immunoassay on the fibroblasts of the bokbunja seed extract was measured as shown in FIG. In the case of the bokbunja seed extract, the effect was 30, 58% at the concentration of 1, 10 μg / ml, and it was confirmed that the efficacy was similar in comparison with the control group EGCG.

이하, 본 발명의 제형예로서 크림, 맛사지크림, 로션, 스킨로션, 에센스, 팩, 클렌징폼의 제형을 예시하고 있으나, 본 발명의 화장품 조성물을 포함하는 제형은 이에 한정되는 것은 아니다.
Hereinafter, formulations of cream, massage cream, lotion, skin lotion, essence, pack, and cleansing foam are exemplified as the formulation examples of the present invention, but the formulations including the cosmetic composition of the present invention are not limited thereto.

제형예Formulation Example 1. 크림조성물 1. Cream composition

유상과 수상을 각각 75 ℃로 가열 혼합한 후 실온으로 냉각한다.The oil phase and water phase are heated to 75 ° C and cooled to room temperature.

Figure pat00001
Figure pat00001

제형예Formulation Example 2.  2. 맛사지크림Massage Cream 조성물 Composition

유상과 수상을 각각 75 ℃로 가열 용해 혼합한 후 실온으로 냉각한다.The oil phase and water phase are mixed by heating at 75 DEG C and then cooled to room temperature.

Figure pat00002
Figure pat00002

제형예Formulation Example 3. 로션 조성물 3. lotion composition

유상과 수상을 각각 75 ℃로 가열 혼합 유화한 후 실온으로 냉각한다.The oil phase and water phase are mixed and emulsified by heating at 75 ° C and then cooled to room temperature.

Figure pat00003

Figure pat00003

제형예Formulation Example 4. 스킨로션 조성물 4. Skin lotion composition

수상과 에탄올상을 각각 제조 혼합한 후 여과한다.The water phase and the ethanol phase are respectively prepared and mixed and then filtered.

Figure pat00004

Figure pat00004

제형예Formulation Example 5. 에센스 조성물 5. Essence composition

수상과 에탄올상을 각각 제조 혼합한 후 여과한다.The water phase and the ethanol phase are respectively prepared and mixed and then filtered.

Figure pat00005
Figure pat00005

제형예Formulation Example 6. 팩 조성물 6. Pack composition

수상과 에탄올상을 각각 분산 용해하여 혼합시킨 후 실온으로 냉각한다.The water phase and the ethanol phase are dispersively dissolved and mixed, and then cooled to room temperature.

Figure pat00006
Figure pat00006

제형예Formulation Example 7.  7. 클렌징폼Cleansing Foam 조성물 Composition

수상과 오일상을 각각 분산 용해하여 혼합 검화한 후 실온으로 냉각한다.The water phase and the oil phase are dispersed and dissolved, mixed and sieved, and then cooled to room temperature.

Figure pat00007
Figure pat00007

상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (6)

복분자 씨 추출물을 유효성분으로 함유하는 미백 및 피부노화 치료 및 예방용 피부외용 약학조성물.A method for the treatment and prevention of skin whitening and skin aging comprising an extract of bokbunja as an active ingredient. 제 1항에 있어서, 상기 피부노화는 주름살, 기미, 주근께, 자외선에 의한 피부 손상, 또는 피부암인 피부외용 약학조성물.[Claim 7] The composition according to claim 1, wherein the skin aging is wrinkle, stain, main muscle, skin damage due to ultraviolet rays, or skin cancer. 제 1항에 있어서, 상기 복분자 씨 추출물은 물, 탄소수 1 내지 4의 저급알코올, 아세톤, 또는 이들의 혼합용매에 추출가능한 추출물임을 특징으로 하는 피부외용 약학조성물.The dermatological pharmaceutical composition according to claim 1, wherein the brambunial seed extract is an extract extractable in water, a lower alcohol having 1 to 4 carbon atoms, acetone, or a mixed solvent thereof. 제 1항에 있어서, 상기 피부외용 약학 조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제 제형을 포함함을 특징으로 하는 피부외용 약학조성물.The dermatological pharmaceutical composition according to claim 1, wherein the dermatological pharmaceutical composition comprises a cream, gel, patch, spray, ointment, warning agent, lotion, liniment, pasta or cataplasma . 복분자 씨 추출물을 유효성분으로 함유하는 미백 및 피부노화 개선 및 예방용 화장료 조성물.A cosmetic composition for improving and preventing whitening and aging of skin comprising an extract of bokbunja as an active ingredient. 제 5항에 있어서 상기 화장료 조성물은 화장수, 스킨, 로션, 영양로션, 영양크림, 마사지 크림, 에센스, 팩의 제형인 것을 특징으로 하는 화장료 조성물.The cosmetic composition according to claim 5, wherein the cosmetic composition is a formulation of lotion, skin, lotion, nutritional lotion, nutritional cream, massage cream, essence, and pack.
KR20130031527A 2013-03-25 2013-03-25 A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening KR101510092B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR20130031527A KR101510092B1 (en) 2013-03-25 2013-03-25 A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130031527A KR101510092B1 (en) 2013-03-25 2013-03-25 A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening

Publications (2)

Publication Number Publication Date
KR20140116665A true KR20140116665A (en) 2014-10-06
KR101510092B1 KR101510092B1 (en) 2015-04-08

Family

ID=51990359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20130031527A KR101510092B1 (en) 2013-03-25 2013-03-25 A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening

Country Status (1)

Country Link
KR (1) KR101510092B1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160080425A (en) 2014-12-29 2016-07-08 경북대학교 산학협력단 Cosmetic composition comprising the extract from solid fermented Terminalia chebula Retz with Phellinus baumii
JP2019030267A (en) * 2017-08-09 2019-02-28 有限会社オービット Activity inhibitor, skin-whitening agent, food and drink and method for producing activity inhibitor
WO2020101221A1 (en) * 2018-11-15 2020-05-22 김영배 Composition containing rubus coreanus oil as active ingredient for improvement of skin barrier functions
KR20210052978A (en) * 2019-11-01 2021-05-11 동신대학교산학협력단 Compositions for Improving Skin Wrinkles Using an Extract of Unripe raspberry
KR20210135837A (en) * 2020-05-06 2021-11-16 휴먼피아코스텍주식회사 Cosmetic composition comprising rubus coreanus pomace extract and preparation method thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102140965B1 (en) 2018-09-10 2020-08-04 (주)비엔텍 Composition comprising extract of dendropanax mobifera and rubus coreanus for preventing and treating vascular disorder
KR102310943B1 (en) 2019-05-16 2021-10-07 재단법인 포항테크노파크 The method for extracting fruit of wild strawberry and Cosmetic composition containing its seed

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100937187B1 (en) * 2007-12-18 2010-01-19 전라북도 고창군 Method for the Preparation of Functional Cosmetics from Bokbunja Wine Processing Waste
KR101212707B1 (en) * 2010-05-26 2012-12-14 재단법인 고창복분자연구소 Cosmetics and toiletries containing extract of Rubus coreanum seeds
KR20120086855A (en) * 2011-01-27 2012-08-06 연세대학교 산학협력단 Anti-allergic Composition Comprising Rubus coreanus Miquel Seed Oil

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160080425A (en) 2014-12-29 2016-07-08 경북대학교 산학협력단 Cosmetic composition comprising the extract from solid fermented Terminalia chebula Retz with Phellinus baumii
JP2019030267A (en) * 2017-08-09 2019-02-28 有限会社オービット Activity inhibitor, skin-whitening agent, food and drink and method for producing activity inhibitor
WO2020101221A1 (en) * 2018-11-15 2020-05-22 김영배 Composition containing rubus coreanus oil as active ingredient for improvement of skin barrier functions
KR20200056819A (en) * 2018-11-15 2020-05-25 김영배 Composition for improving skin barrier function comprising rubus coreanus miquel oil
KR20210052978A (en) * 2019-11-01 2021-05-11 동신대학교산학협력단 Compositions for Improving Skin Wrinkles Using an Extract of Unripe raspberry
KR20210135837A (en) * 2020-05-06 2021-11-16 휴먼피아코스텍주식회사 Cosmetic composition comprising rubus coreanus pomace extract and preparation method thereof

Also Published As

Publication number Publication date
KR101510092B1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
KR101510092B1 (en) A composition comprising the seed extract of Rubus coreanus M for preventing and treating skin aging and for skin whitening
KR101513892B1 (en) A Method for producing a purified extract containing abundant amoun of tanshinone I and tanshinone IIA showing anti-oxidative activity, skin whitening activity and anti-wrinkle activity from Salvia miltiorrhiza BUNGE
KR101086736B1 (en) Composition comprising a crude complex herb extract showing anti-aging and anti-wrinkle activity
KR20140056487A (en) A topical composition comprising the extract of persimmon calyx or trifolin isolated therefrom as an active ingredient for preventing and treating skin wrinkle and for skin-whitening
KR20100094614A (en) Cosmetic composition comprising an extract of black garlic having skin whitening and wrinkle improving activity
KR101749669B1 (en) Topical composition comprising the isolated compounds from Rubus coreanus seed showing skin whitening effect
KR101243219B1 (en) Skin whitening and anti-wrinkle composition comprising a fermented plant extract in Ulleung island
KR20160121074A (en) A composition comprising an seed extract of Vitex trifolia L. for skin whitening and anti-aging activity
KR101458013B1 (en) Composition for anti-oxidation and whitening and anti-wrinkle cosmetics comprising extract of un-ripening Pinus koraiensis Siebold et Zucc cone
KR101499453B1 (en) Skin whitening composition comprising complex herbal extract
KR20120036011A (en) Composition comprising a leaf extract of isatis tinctoria l. showing skin whitening and anti-wrinkle activity
KR20140116666A (en) Skin whitening and anti-skin aging composition comprising complex herbal extract
KR101646347B1 (en) Anti-oxidant and skin whitening composition comprising a pine cone extract
KR101510939B1 (en) Composition containing extracts of wheat bran as an active ingredient for preventing of hair loss or for promoting hair growth
KR101541842B1 (en) Skin composition comprising the extract of fermented chestnut bur showing skin whitening and anti-aging or anti-inflammatory activity
KR101873244B1 (en) Skin composition comprising the sprouting seed extract of Schisandra chinensis for anti-wrinkle or anti-inflammatory activity
KR101230588B1 (en) Cosmetics Composite
KR20140004330A (en) A composition comprising the compound isolated from fructus extract of arctium luppa l for preventing and treating wrinkle
KR100614467B1 (en) Cosmetic composition comprising the extract mixture of euphorbia helioscopia l., paeonia suffruticosa andr. and aloe vera l. having inhibition activity of melanin synthesis
KR20140033609A (en) A composition comprising the compounds isolated from extract of carthamus tinctorious seeds as an active ingredient for preventing and treating skin aging related disease
KR101371126B1 (en) A method for preparing abundant oil component showing potent tyrosinase inhibiting activity
KR101570123B1 (en) Cosmetic Composition Comprising Extract of testa of Pinus koraiensis Siebold et Zucc
KR102690549B1 (en) Functional composition containing Salicornia extract as an active ingredient
KR101238963B1 (en) Skin whitening composition comprising complex herbal extract
KR20060031007A (en) Cosmetic composition comprising the extract of gastrodia elata blume and the compound isolated therefrom having skin whitening effect

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
FPAY Annual fee payment

Payment date: 20190515

Year of fee payment: 5